Related Experiment Video
Updated: May 26, 2026

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
The role of inflammation in the immune evasion of KRas
E Jane Homan1, Robert D Bremel1
1ioGenetics LLC, Madison, WI, United States.
Abstract:
KRas, NRas and HRas mutations are recognized in over 25% of all tumors, with the predominant mutations occurring at amino acids G12 or G13. While small molecule inhibitors of KRas show therapeutic promise, KRas has largely resisted control by immunotherapy in clinical cases, although immune responses may be detected following vaccination. Inflammation is a recognized precursor of most KRas-associated tumors. In inflammation cathepsin B leaks from the lysosome and at the higher pH of the cytoplasm acquires endopeptidase activity, in addition to its exopeptidase role. Cathepsin B is consistently upregulated in tumors and its role in tumorigenesis has been attributed to increased apoptosis and digestion of the extracellular matrix. Here we examine the effect of cathepsin B on neoepitopes in KRas. We predict that cathepsin B cleavage patterns of KRas may lead to the destruction of the G12 and G13 mutant neoepitope peptides that would otherwise bind to MHC I, thereby rendering them immunologically invisible. We review reports of the interaction of cathepsin B with trypsinogen in the pancreas and caspases in inflammasomes and the potential effect of premature activation of trypsin on immune evasion of G12R mutants. We summarize our observations and literature review in a schematic describing the potential role inflammation and the actions of cathepsin B, trypsin, and caspases on the immune evasion of KRas and related Ras family gene products.
Insights
Inflammation-induced cathepsin B may degrade KRas mutant neoepitopes, hiding them from immune detection. This mechanism, involving cathepsin B, trypsin, and caspases, contributes to KRas-driven tumor immune evasion.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Ras family proteins (KRas, NRas, HRas) are mutated in over 25% of human tumors, primarily at G12 or G13.
- KRas mutations are linked to inflammation, a known tumor precursor.
- While KRas inhibitors show promise, KRas-driven tumors often resist immunotherapy.
Purpose of the Study:
- To investigate the impact of cathepsin B on KRas neoepitopes.
- To elucidate the role of inflammation-associated enzymes in KRas-driven tumor immune evasion.
Main Methods:
- Literature review of cathepsin B, trypsin, and caspase interactions.
- Analysis of cathepsin B's effect on KRas neoepitope peptides.
- Schematic representation of proposed immune evasion mechanisms.
Main Results:
- Cathepsin B, upregulated in tumors, may cleave KRas G12/G13 mutant neoepitopes.
- This cleavage could prevent neoepitope binding to MHC I, rendering them immunologically invisible.
- Interactions with trypsin and caspases may further facilitate immune evasion.
Conclusions:
- Cathepsin B-mediated degradation of neoepitopes is a potential mechanism for KRas tumor immune evasion.
- Inflammation and associated enzymes play a critical role in the immune escape of Ras family-driven cancers.
Related Concept Videos
The Ras Gene
Ras is a superfamily...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The JAK-STAT Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Extrinsic Apoptotic Pathway
